AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1146857 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study 30739922 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Based Health Insurance (CBHI) scheme enrollment
Number of subjects: 416
Study 28342891 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Acceptance and Commitment Therapy (GACT)
Number of subjects: 156
Study 28342891 — intervention group
Group type: COMPARATOR
Intervention: Recommended Pharmacological Treatment (RPT)
Number of subjects: 156
Study 28342891 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 156
Study 28342891 — intervention group
Group type: EXPERIMENTAL
Intervention: GACT vs RPT
Number of subjects: 156
Study 25702072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone assessment
Number of subjects: 469
Study 25702072 — intervention group
Group type: COMPARATOR
Intervention: Paper assessment
Number of subjects: 469
Study 25702072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile assessment
Number of subjects: 469
Study 22893323 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐KG and 5‐HMF supplementation (AO1)
Number of subjects: 18
Study 22893323 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad based antioxidant supplementation (AO2)
Number of subjects: 18
Study 22893323 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PL)
Number of subjects: 18
Study 21511380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow‐Gates mandibular nerve block
Number of subjects: 20
Study 21511380 — intervention group
Group type: COMPARATOR
Intervention: Control (no Gow‐Gates block)
Number of subjects: 20
Study 18202588 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 71
Study 17203122 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 90
Study 17203122 — intervention group
Group type: COMPARATOR
Intervention: atracurium (priming with 0.05 mg/kg followed by 0.55 mg/kg after induction of anaesthesia)
Number of subjects: 90
Study 14679270 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab, 1 mg/kg, 12 weekly doses
Number of subjects: 556
Study 14679270 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 556
Study 11307041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg oral dose
Number of subjects: 12
Study 9722127 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 5 days
Number of subjects: 152
Study 9722127 — intervention group
Group type: EXPERIMENTAL
Intervention: vaginal ornidazole 500 mg/day for 5 days
Number of subjects: 152
Study 9722127 — intervention group
Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose
Number of subjects: 152
Study 9722127 — intervention group
Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose and vaginal ornidazole 500 mg/day for 5 days
Number of subjects: 152
Study 9722127 — intervention group
Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose and vaginal metronidazole 2 x 500 mg/day for 7 days
Number of subjects: 152
Study 9722127 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 5 days and vaginal metronidazole 2 x 500 mg/day for 7 days
Number of subjects: 152
Study 9722127 — intervention group
Group type: EXPERIMENTAL
Intervention: vaginal metronidazole 2 x 500 mg/day for 7 days
Number of subjects: 152
Study 7978130 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 2 micrograms.ml‐1 in 0.9% sodium chloride
Number of subjects: 60
Study 7978130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms.ml‐1 + adrenaline 2.5 micrograms.ml‐1
Number of subjects: 60
Study 7978130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms.ml‐1 + clonidine 3 micrograms.ml‐1
Number of subjects: 60
Study 2531992 — intervention group
Group type: COMPARATOR
Intervention: IA (Intraarterial FUdR, 0.2 mg/kg/d x 14 days/month)
Number of subjects: 52
Study 2531992 — intervention group
Group type: EXPERIMENTAL
Intervention: IA/IV (Intraarterial FUdR + systemic 5‐FU 700 mg/m2/d x 3 days/month)
Number of subjects: 52
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: SGaw (specific airway conductance)
Number of subjects: 24
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: MMEF (maximum mid expiratory flow)
Number of subjects: 24
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: CV (closing volume)
Number of subjects: 24
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 (forced expiratory volume in one second)
Number of subjects: 24
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC (forced vital capacity)
Number of subjects: 24
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: MMEF (measured by spirometry)
Number of subjects: 24
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: SGaw (measured by body plethysmography)
Number of subjects: 24
Study 1187279 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-volume parameters (measured by wedge spirometer)
Number of subjects: 24
Study 31834936 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application providing information and support for medication abortion (MA)
Number of subjects: 0
Study 31834936 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (high-quality comprehensive and empathic counseling on pregnancy options)
Number of subjects: 0
Study 31018852 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to quitline via warm handoff
Number of subjects: 1054
Study 31018852 — intervention group
Group type: COMPARATOR
Intervention: Referral to quitline via fax
Number of subjects: 1054
Study 31018852 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of smoking cessation medications while hospitalized
Number of subjects: 1054
Study 31018852 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge with a prescription
Number of subjects: 1054
Study 31018852 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of medication as an inpatient
Number of subjects: 1054
Study 30059262 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 419
Study 30059262 — intervention group
Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 419
Study 30059262 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 419
Study 27221962 — intervention group
Group type: COMPARATOR
Intervention: Group I (control)
Number of subjects: 161
Study 27221962 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 161
Study 27221962 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III
Number of subjects: 161
Study 27221962 — intervention group
Group type: EXPERIMENTAL
Intervention: Native thiol
Number of subjects: 161
Study 27221962 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiol values of 310.7 or below
Number of subjects: 161
Study 24465387 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic interpersonal therapy (PIT)
Number of subjects: 0
Study 24465387 — intervention group
Group type: COMPARATOR
Intervention: Enhanced medical care (control)
Number of subjects: 0
Study 22436453 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 μg/day) supplementation for 3 years
Number of subjects: 0
Study 22436453 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 20625317 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 110
Study 20625317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 110
Study 17981247 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement (S group = 98 patients)
Number of subjects: 201
Study 17981247 — intervention group
Group type: COMPARATOR
Intervention: Non-stent placement (nS group = 103 patients)
Number of subjects: 201
Study 17981247 — intervention group
Group type: COMPARATOR
Intervention: Non-stent placement (nS group)
Number of subjects: 201
Study 15726878 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg) + Triamterene (150 mg)
Number of subjects: 0
Study 15726878 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 mg)
Number of subjects: 0
Study 15726878 — intervention group
Group type: COMPARATOR
Intervention: Triamterene (150 mg)
Number of subjects: 0
Study 12049800 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) low dosage (100 mg daily)
Number of subjects: 30
Study 12049800 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) medium dosage (200 mg daily)
Number of subjects: 30
Study 10090547 — intervention group
Group type: COMPARATOR
Intervention: High-dose inhaled budesonide (1600 microg d(-1) for 3 d and 800 microg for 7 d)
Number of subjects: 40
Study 10090547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betamethasone (6, 4 and 2 mg for 3 d)
Number of subjects: 40
Study 7788149 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (10 mg/day for first 12 weeks, tapering to 7.5 mg/day for weeks 13-14, 5 mg/day for weeks 15-16, and 2.5 mg/day for weeks 17-18)
Number of subjects: 40
Study 7788149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7788149 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (after tapering)
Number of subjects: 40
Study 2169368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study 376140 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic results from Mycosis Fungoides Cooperative Group protocols
Number of subjects: 376
Study 31608832 — intervention group
Group type: EXPERIMENTAL
Intervention: IFM strengthening exercises for ten weeks
Number of subjects: 20
Study 31608832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 20
Study 28024931 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flux Hemodialysis (HD)
Number of subjects: 100
Study 28024931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 100
Study 25968407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 80 mg
Number of subjects: 30
Study 25968407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 30
Study 25968407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25968407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (both doses)
Number of subjects: 30
Study 24280904 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based deep breathing exercises with a positive expiratory pressure device (10-15 cm H2O), 30 slow deep breaths, 5 times a day for 2 months
Number of subjects: 159
Study 24280904 — intervention group
Group type: COMPARATOR
Intervention: Control group performing no breathing exercises after discharge (n = 154)
Number of subjects: 159
Study 22530773 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-insufflated ESD with duodenal balloon occlusion (duodenal balloon group)
Number of subjects: 44
Study 22530773 — intervention group
Group type: COMPARATOR
Intervention: Regular CO2-insufflated ESD (regular group)
Number of subjects: 44
Study 22530773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 19138366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of testosterone and vardenafil
Number of subjects: 13
Study 19138366 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 13
Study 19138366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19138366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 13
Study 17519644 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine+lithium/divalproex
Number of subjects: 200
Study 17519644 — intervention group
Group type: COMPARATOR
Intervention: Placebo+lithium/divalproex
Number of subjects: 200
Study 15009968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiring nitric oxide (NO) at 20±1 mg/L for 30 minutes before admission and urokinase (150x10^4 U) intravenously injected with 0.9% sodium chloride within 30 minutes
Number of subjects: 60
Study 15009968 — intervention group
Group type: COMPARATOR
Intervention: Urokinase treatment as in test group
Number of subjects: 60
Study 15009968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiring nitric oxide (NO) before urokinase
Number of subjects: 60
Study 11583938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal
Number of subjects: 0
Study 11583938 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 9845708 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg daily)
Number of subjects: 71
Study 9845708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 9877146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 80% VO2max until exhaustion
Number of subjects: 18
Study 9877146 — intervention group
Group type: COMPARATOR
Intervention: Cycling at 55% VO2max for 3 hours or to fatigue
Number of subjects: 18
Study 1675705 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole, 2.5 mg/kg on alternate days (31 patients)
Number of subjects: 61
Study 1675705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 patients)
Number of subjects: 61
Study 6822042 — intervention group
Group type: EXPERIMENTAL
Intervention: B15000 (Iopamidol)
Number of subjects: 0
Study 6822042 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 370
Number of subjects: 0
Study 6822042 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 370 plus Lignocaine
Number of subjects: 0
Study 31075274 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Aβ42 oligomers
Number of subjects: 0
Study 31075274 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger Aβ42 aggregates
Number of subjects: 0
Study 30219038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial cigarette pack warnings
Number of subjects: 24
Study 26796394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 453
Study 26796394 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 453
Study 26796394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support (LVAD)
Number of subjects: 453
Study 26796394 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage heart failure patients (N=41)
Number of subjects: 453
Study 24828363 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cooling to a target body temperature of 34-35°C, started within six hours of symptom onset and maintained for 24 hours)
Number of subjects: 1500
Study 24828363 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 1500
Study 22456865 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) trajectory in individuals who developed diabetes
Number of subjects: 1722
Study 22456865 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) in individuals who developed diabetes 10 years after baseline
Number of subjects: 1722
Study 22456865 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) increase from 3 years to 1 year prediagnosis
Number of subjects: 1722
Study 22456865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HbA(1c) and FPG increase in the entire group
Number of subjects: 1722
Study 20197618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholi acid combined with reduced glutathione
Number of subjects: 84
Study 20197618 — intervention group
Group type: COMPARATOR
Intervention: Yinzhihuang intravenously combined with reduced glutathione
Number of subjects: 84
Study 18422579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 102
Study 18422579 — intervention group
Group type: EXPERIMENTAL
Intervention: Choreito (7.5 g/day)
Number of subjects: 102
Study 18422579 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 102
Study 16226266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) consumption (50ml per day for 3 months)
Number of subjects: 20
Study 16226266 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 12696391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1: Sporadic, brief (30 seconds‐1 minute) and unstructured medical advice to quit.
Number of subjects: 217
Study 12696391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2: Brief (5‐8 minutes) structured medical counselling for tobacco quitting, followed by reinforcement advice on 3 occasions during 3 months, accompanied by nicotine patches individualized according to nicotine dependence.
Number of subjects: 217
Study 10656203 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional polymeric enteral diet (Group A)
Number of subjects: 40
Study 10656203 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-rich and lactose-free polymeric diet (Group B)
Number of subjects: 40
Study 9068017 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 mmol/L bicarbonate-buffered CAPD solution
Number of subjects: 9
Study 9068017 — intervention group
Group type: COMPARATOR
Intervention: 34 mmol/L bicarbonate-buffered CAPD solution
Number of subjects: 9
Study 8446394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg b.i.d. for 7 days (n = 134)
Number of subjects: 270
Study 8446394 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 13.5 mg/kg t.i.d. for 7 days (n = 136)
Number of subjects: 270
Study 3510320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (2 intravenous doses preoperatively)
Number of subjects: 181
Study 3510320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 29240208 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium (Ti) post
Number of subjects: 31
Study 29240208 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia (Zi) post
Number of subjects: 31
Study 29240208 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-fiber (Gf) post
Number of subjects: 31
Study 29240208 — intervention group
Group type: EXPERIMENTAL
Intervention: No post (NP)
Number of subjects: 31
Study 29240208 — intervention group
Group type: COMPARATOR
Intervention: Control tooth (vital)
Number of subjects: 31
Study 26576750 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin 500 IU·kg(‐1)
Number of subjects: 66
Study 26576750 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 66
Study 24993838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin collagen implant (GCI)
Number of subjects: 171
Study 24993838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GCI)
Number of subjects: 171
Study 22421244 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (amphotericin B 1 mg/kg per day and 5FC 100 mg/kg per day for 2 weeks)
Number of subjects: 88
Study 22421244 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNγ two doses (standard therapy plus IFNγ1b 100 μg on days 1 and 3)
Number of subjects: 88
Study 22421244 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNγ six doses (standard therapy plus IFNγ1b 100 μg on days 1, 3, 5, 8, 10, and 12)
Number of subjects: 88
Study 21054874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (exact dosage and duration not specified)
Number of subjects: 1053
Study 21054874 — intervention group
Group type: COMPARATOR
Intervention: Screening question responses (no, yes, unsure)
Number of subjects: 1053
Study 21054874 — intervention group
Group type: COMPARATOR
Intervention: Mean number of risk factors
Number of subjects: 1053
Study 17991308 — intervention group
Group type: EXPERIMENTAL
Intervention: BSPCI delivering 258 microg of ET
Number of subjects: 23
Study 17991308 — intervention group
Group type: COMPARATOR
Intervention: Sublingual ET (2 mg tablet)
Number of subjects: 23
Study 17991308 — intervention group
Group type: EXPERIMENTAL
Intervention: BSPCI delivering 129 microg of ET
Number of subjects: 23
Study 17991308 — intervention group
Group type: COMPARATOR
Intervention: Metered-dose inhaler delivering 2052 microg of ET
Number of subjects: 23
Study 16305008 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply White dentifrice (CSW)
Number of subjects: 0
Study 16305008 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control Whitening (CTW)
Number of subjects: 0
Study 11865557 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyretic treatment during febrile episodes
Number of subjects: 0
Study 11865557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam as intermittent prophylaxis
Number of subjects: 0
Study 11865557 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous anticonvulsant treatment
Number of subjects: 0
Study 8060802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0
Study 3111166 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose intravenous infusion
Number of subjects: 24
Study 3111166 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose intravenous infusion
Number of subjects: 24
Study 29189337 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous endurance training (CET)
Number of subjects: 127
Study 29189337 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength endurance training (SET)
Number of subjects: 127
Study 29189337 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval endurance training (IET)
Number of subjects: 127
Study 29189337 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 127
Study 28903957 — intervention group
Group type: EXPERIMENTAL
Intervention: Skewed protein distribution (10 g at breakfast, 20 g at lunch, and 60 g at dinner; n = 20)
Number of subjects: 41
Study 28903957 — intervention group
Group type: COMPARATOR
Intervention: Even protein distribution (30 g each at breakfast, lunch, and dinner; n = 21)
Number of subjects: 41
Study 26141379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine hCG application (cohort A)
Number of subjects: 1186
Study 26141379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine hCG application (cohort B)
Number of subjects: 1186
Study 26141379 — intervention group
Group type: COMPARATOR
Intervention: Control group (culture medium) (cohort A)
Number of subjects: 1186
Study 26141379 — intervention group
Group type: COMPARATOR
Intervention: Control group (culture medium) (cohort B)
Number of subjects: 1186